- Home
- AES vs BMRN Comparison
AES vs BMRN Comparison
Compare AES & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- BMRN
- Stock Information
- Founded
- AES 1981
- BMRN 1996
- Country
- AES United States
- BMRN United States
- Employees
- AES N/A
- BMRN N/A
- Industry
- AES Electric Utilities: Central
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AES Utilities
- BMRN Health Care
- Exchange
- AES Nasdaq
- BMRN Nasdaq
- Market Cap
- AES 9.6B
- BMRN 10.5B
- IPO Year
- AES 1991
- BMRN 1999
- Fundamental
- Price
- AES $13.69
- BMRN $54.58
- Analyst Decision
- AES Buy
- BMRN Buy
- Analyst Count
- AES 10
- BMRN 18
- Target Price
- AES $15.44
- BMRN $90.00
- AVG Volume (30 Days)
- AES 9.3M
- BMRN 2.9M
- Earning Date
- AES 11-04-2025
- BMRN 10-27-2025
- Dividend Yield
- AES 5.21%
- BMRN N/A
- EPS Growth
- AES N/A
- BMRN 59.53
- EPS
- AES 1.46
- BMRN 2.68
- Revenue
- AES $12,094,000,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- AES $1.04
- BMRN $13.32
- Revenue Next Year
- AES $4.54
- BMRN $7.51
- P/E Ratio
- AES $9.07
- BMRN $20.40
- Revenue Growth
- AES N/A
- BMRN 12.39
- 52 Week Low
- AES $9.46
- BMRN $50.76
- 52 Week High
- AES $15.51
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- AES 44.98
- BMRN 54.08
- Support Level
- AES $13.61
- BMRN $51.99
- Resistance Level
- AES $14.11
- BMRN $55.34
- Average True Range (ATR)
- AES 0.52
- BMRN 1.45
- MACD
- AES -0.06
- BMRN 0.09
- Stochastic Oscillator
- AES 33.45
- BMRN 81.88
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.